

Appl. No. 09/762,294
Response dated August 13, 2003
Reply to Office action of July 17, 2003

REMARKS/ARGUMENTS

By the present amendment, claims 9-12 and 15-16 have been amended to replace "NSS" with "signal sequence" and claims 17-18 have been amended to replace "positive" with "positively charged" to render these claims consistent with the language used in the other claims. Non-elected claims 22-30 have been canceled.

Applicant provisionally elects Group I, the claim readable thereon as being claims 1-21, which are drawn to a non-cytolytic recombinant human immunodeficiency virus wherein the natural signal sequence (NSS) has been modified or replaced and attendant method of use. This is without prejudice to Applicant filing divisional applications to the Groups II-IV inventions.

The Commissioner is hereby authorized to charge any fee (including any claim fee) which may be required to our Deposit Account No. 02-2095.

In view of the foregoing comments and amendments, we respectfully submit that the application is in order for allowance and early indication of that effect is respectfully requested. Should the Examiner deem it beneficial to discuss the application in greater detail, he is kindly requested to contact the undersigned by telephone at (416) 957-1682 at his convenience.

Respectfully submitted,

BERESKIN & PARR

By M. Gravelle
Micheline Gravelle
Reg. No. 40,261

OFFICIAL

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario
Canada M5H 3Y2
Tel: 416-957-1682
Fax: 416-361-1398